Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715266 | 0.83 | ALOX5 (0.42) | ALOX5CTSSCTSK | |
| SCHEMBL3897727 | 0.83 | ALOX5 (0.42) | ALOX5CTSSCTSK | |
| SCHEMBL186630 | 0.83 | ALOX5 (0.42) | ALOX5CTSSCTSK | |
| SCHEMBL1222928 | 0.82 | PTGS2 (0.42) | PTGS2CYP2C9CYP2C19CTSSCTSK | |
| SCHEMBL17254362 | 0.81 | ALOX5 (0.49) | CYP1A2CYP2C9CYP2C19ALOX5CTSS | |
| SCHEMBL17241438 | 0.81 | ALOX5 (0.49) | CYP1A2CYP2C9CYP2C19ALOX5CTSS | |
| SCHEMBL17241382 | 0.80 | MAPT (0.38) | GAA | |
| SCHEMBL1221765 | 0.79 | PTGS2 (0.39) | PTGS2CTSSCTSK | |
| SCHEMBL5780065 | 0.79 | TYR (0.44) | — | |
| SCHEMBL17254313 | 0.78 | ALOX5 (0.33) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| US-7432258-B2 | Morpholinyl and pyrrolidinyl analogs | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432258-B2 | Morpholinyl and pyrrolidinyl analogs | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432258-B2 | Morpholinyl and pyrrolidinyl analogs | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2008011551-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | PTGS2 185/4885CYP1A2 2653/4885GAA 606/4885 |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | PTGS2 185/4885CYP1A2 2653/4885GAA 606/4885 |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | UTS2R, PLAUR, FABP3 | PTGS2 13/4885CYP1A2 1610/4885GAA 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.